shutterstock_1014176104_willy_barton

Willy Barton / Shutterstock.com

16 June 2020Big PharmaRory O'Neill

UKIPO cancels SPC extension at owner’s request

The UK Intellectual Property Office has agreed to revoke an extension to a supplementary protection certificate (SPC) for immunosuppressant tocilizumab, at the request of the owners.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Unitary SPC should follow new patent system: EC official

11 June 2020 The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

15 May 2020 The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

More on this story

Unitary SPC should follow new patent system: EC official

11 June 2020 The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

15 May 2020 The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

More on this story

Unitary SPC should follow new patent system: EC official

11 June 2020 The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

15 May 2020 The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent